TITLE

INTERCELL OUTLICENSES GROUP B STREPTOCOCCUS VACCINE

PUB. DATE
February 2009
SOURCE
Worldwide Biotech;Feb2009, Vol. 21 Issue 2, p2
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on Intercell's transfer of its pre-clinical Group B Streptococcus (GBS) vaccine program to Novartis. However, co-exclusive rights for the development of therapeutic antibodies against GBS have been retained and received by Intercell. Additional rights on GBS antibodies have also been in-licensed by the company from Novartis.
ACCESSION #
36237377

 

Related Articles

  • Novartis makes vaccines play.  // ICIS Chemical Business Americas;7/9/2007, Vol. 272 Issue 2, p30 

    The article reports that vaccine developer Intercell and pharmaceutical firm Novartis have entered into an alliance that will broaden Novartis' vaccine business.

  • Tech startup of the month. Peterson, Eric // ColoradoBiz;May2002, Vol. 29 Issue 5, p49 

    Features the GlobeImmune Inc. in Denver, Colorado. Production of vaccine from brewer's yeast proteins; Focus on the HIV disease; Licensing agreement with Novartis.

  • products showcase.  // Pharmacy Today;May2009, Vol. 15 Issue 5, p14 

    The article presents several drugs that are approved by the U.S. Food and Drug Administration. It includes Novartis AG's everolimus, an mammalian target of rapamycin (mTOR) inhibitor, for the treatment of patients with advanced renal cell carcinoma, Sciele Pharma Inc.'s benzyl alcohol lotion for...

  • Intercell Receives Good Phase II News On HCV Vaccine Candidate. Sheridan, Cormac // BioWorld International;8/22/2007, Vol. 12 Issue 34, p2 

    The article reports on the proof-of-concept data received by Intercell AG in a Phase II clinical trial of hepatitis C virus (HCV) vaccine IC41-202. It states that the Vienna, Austria-based company is planning to combine the product with that of its strategic partner Novartis AG in a prime-boost...

  • Intercell Looking for 'Renewal' After S. Aureus Vaccine Failure. Boggs, Jennifer // BioWorld Today;6/9/2011, Vol. 22 Issue 111, p1 

    The article reports on the failure of the prophylactic vaccine against Staphylococcus aureus infections by Intercell AG in its Phase II/III study. It says that the results decreased the shares of the Austria-based biotechnology firm by 22 percent. Meanwhile, Intercell is still optimistic because...

  • Vaccines Firm Goes to Vivalis In All-Share Deal Worth $175M. Moran, Nuala // BioWorld International;12/19/2012, Vol. 17 Issue 51, p3 

    The article reports on the acquisition of Intercell AG by French vaccines manufacturing technology firm Vivalis SA. Valneva is the name of the merged company, which intends to raise 40 million euros via a rights issue. On December 17, 2012, the share price of Intercell rose by 13% and settled at...

  • Novartis Postpones Decision on Pseudomonas Vaccine. Sheridan, Cormac // BioWorld International;4/6/2011, Vol. 16 Issue 14, p1 

    This article reports on the move of Intercell AG and Novartis AG to postpone their strategic alliance on a Pseudomonas aeruginosa vaccine in 2011. The companies made the decision until efficacy data from a trial is available. Gerd Zettlmeissl, chief executive officer (CEO) of Intercell,...

  • Intercell Shares Rise On Novartis Pact, $366M Committed Cash. Sheridan, Cormac // BioWorld Today;7/5/2007, Vol. 18 Issue 129, p1 

    The article reports on the alliance between Intercell and Novartis AG. Shares in Intercell increased after the company formed an alliance with Novartis. The deal focuses on three aspects of Intercell's pipeline including the synthetic adjuvant IC31, the Antigen Identification Program and a...

  • Novartis: increasing presence in vaccines.  // PharmaWatch: Monthly Review;Aug2007, Vol. 6 Issue 8, p23 

    The article reports on the extension of the alliance between Novartis AG and Intercell AG. The agreement allows Novartis to access more than 10 unpartnered projects in the Intercell portfolio to potentially develop vaccine programs. The agreement also focuses on the development of vaccines...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics